Indacaterol provides sustained 24 h bronchodilation on once-daily dosing in asthma: A 7-day dose-ranging study
Academic Article
Publication Date:
2008
Short description:
Indacaterol provides sustained 24 h bronchodilation on once-daily dosing in asthma: A 7-day dose-ranging study / C., Laforce; M., Alexander; R., Deckelmann; Fabbri, Leonardo; Z., Aisanov; R., Cameron; R., Owen; M., Higgins. - In: ALLERGY. - ISSN 0105-4538. - STAMPA. - 63:1(2008), pp. 103-111. [10.1111/j.1398-9995.2007.01555.x]
abstract:
BACKGROUND: Indacaterol is a novel, once-daily beta(2)-agonist in development for the treatment of asthma and chronic obstructive pulmonary disease. Studies were required to determine optimal dose(s) for continuing investigation. OBJECTIVE: A dose-ranging study was undertaken to evaluate efficacy and safety of indacaterol. METHODS: A total of 436 patients with persistent asthma receiving inhaled corticosteroids were randomized to 7 days treatment with once-daily indacaterol 50, 100, 200, or 400 microg via multi-dose dry-powder inhaler (MDDPI; Certihaler), indacaterol 400 microg via single-dose dry-powder inhaler (SDDPI), or placebo. Serial 24-h spirometry was performed on days 1 and 7. Vital signs, laboratory evaluations, and adverse events were monitored. RESULTS: All doses of indacaterol increased the mean time-standardized area under the curve of forced expiratory volume in 1 s (FEV(1)) from 22 to 24 h postdose (P
Iris type:
Articolo su rivista
Keywords:
Asthma; diagnosis; drug therapy.
List of contributors:
C., Laforce; M., Alexander; R., Deckelmann; Fabbri, Leonardo; Z., Aisanov; R., Cameron; R., Owen; M., Higgins
Published in: